Clinical Data Arthrosi drug trial in gout delivers for new owner Sobi PharmaphorumSobi's $1.5 billion takeover of Arthrosi at the end of 2025 has started to pay off, with a positive phase 3 trial for gout therapy pozdeutinurad.Immunology & InflammationRead full story pharminent May 26, 2026 (Last updated: May 27, 2026) Pharmaphorum Sobi’s $1.5 billion takeover of Arthrosi at the end of 2025 has started to pay off, with a positive phase 3 trial for gout therapy pozdeutinurad. Immunology & Inflammation Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly’s Verve gambit pays off as base editor cuts cholesterol in early studyNext: Eli Lilly to buy trio of vaccine developers in $3.8bn outlay Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
